Literature DB >> 11870685

Bent spine syndrome: computed tomographic study and isokinetic evaluation.

Michel Laroche1, Geraldine Ricq, Marie-Bernadette Delisle, Michel Campech, Philippe Marque.   

Abstract

Primary acquired lumbar kyphosis of the adult, or bent spine syndrome, is probably secondary to late-onset muscle dystrophy preferentially involving the paravertebral muscles. In order to better define the extent of this myopathy, we compared spinal computerized tomography scans and muscle force, power, and fatigability, assessed by isokinetic tests, of the spinal erector and pelvic and shoulder girdle muscles in 23 patients with primary acquired lumbar kyphosis (20 women and 3 men, mean age 72.8 years) and 15 matched control subjects. Patients had decreased spinal and shoulder muscle density. Force, power, and work done were reduced in their paravertebral muscles, whereas in the scapular and gluteus medius muscles only work done after a series of 20 rapid movements showed a decrease. Primary acquired lumbar kyphosis in the adult may be considered as a late-onset girdle myopathy with subclinical involvement of the muscles of the pelvic and shoulder girdles. Copyright 2002 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11870685     DOI: 10.1002/mus.10016

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

Review 1.  Camptocormia: the bent spine syndrome, an update.

Authors:  Thibaut Lenoir; Nathalie Guedj; Philippe Boulu; Pierre Guigui; Michel Benoist
Journal:  Eur Spine J       Date:  2010-03-19       Impact factor: 3.134

2.  Camptocormia in Parkinson's disease.

Authors:  Kazuo Abe; Yutaka Uchida; Masaru Notani
Journal:  Parkinsons Dis       Date:  2010-06-30

Review 3.  Bent spine syndrome as an initial manifestation of late-onset multiple acyl-CoA dehydrogenase deficiency: a case report and literature review.

Authors:  Yufen Peng; Min Zhu; Junjun Zheng; Yuanzhao Zhu; Xiaobing Li; Caixia Wei; Daojun Hong
Journal:  BMC Neurol       Date:  2015-07-24       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.